XML 107 R61.htm IDEA: XBRL DOCUMENT
v3.25.1

Significant events for the years ended December 31, 2022, 2023 and 2024 and subsequent events - For the year ended 2023 (Details) € / shares in Units, $ / shares in Units, € in Thousands, $ in Millions |  |  |  |  |  |  |  |  |  |  |  | 1 Months Ended | 6 Months Ended | 12 Months Ended | 18 Months Ended | 121 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 02, 2023 EUR (€) | Oct. 24, 2023 EUR (€) € / shares shares | Oct. 24, 2023 USD ($) shares | Aug. 24, 2023 EUR (€) | Aug. 22, 2023 EUR (€) | Aug. 21, 2023 EUR (€) | Aug. 20, 2023 EUR (€) transaction € / shares | May 24, 2023 € / shares shares | Feb. 22, 2023 EUR (€) € / shares shares | Sep. 07, 2022 EUR (€) € / shares shares | Sep. 02, 2022 EUR (€) transaction € / shares shares | Jul. 30, 2021 EUR (€) € / shares shares | Oct. 31, 2020 shares | Dec. 31, 2023 shares plan € / shares | Dec. 31, 2024 EUR (€) shares € / shares | Dec. 31, 2023 EUR (€) € / shares shares | Dec. 31, 2022 EUR (€) € / shares shares | Dec. 31, 2024 shares € / shares | Dec. 31, 2023 EUR (€) € / shares | Nov. 19, 2024 € / shares | Oct. 24, 2023 $ / shares
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase from issuance of ordinary shares |  |  |  |  |  |  |  |  | € 130,000 | € 46,231 |  |  |  |  |  | € 353,377 | € 46,231 |  |  |  |
Capital increase from issuance of ordinary shares (in shares) | shares |  | 20,325,500 | 20,325,500 |  |  |  |  |  | 20,000,000 | 5,530,000 |  |  |  |  |  | 40,325,500 | 5,530,000 |  |  |  |
Par value per share (in euro per share) | € / shares |  | € 0.01 |  |  |  |  |  | € 0.01 | € 0.01 | € 0.01 |  |  |  | € 0.01 | € 0.01 | € 0.01 | € 0.01 | € 0.01 | € 0.01 | € 0.01 |
Equity issuance, subscripion price per share (in euro per share) | € / shares |  |  |  |  |  |  |  |  | € 6.50 | € 8.36 |  |  |  |  |  |  |  |  |  |  |
Share issue related cost |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 28,111 | € 3,280 |  |  |  |
Exercises of share warrants (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  | 464,309 |  | 4,000 |  | 19,134 |  |  |  |
Proceeds from borrowings |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 175,000 |  |
Repayments of convertible loan notes |  |  |  | € 33,000 |  |  |  |  |  |  |  |  |  |  | € 8,750 | 27,188 | € 0 |  |  |  |
Capital increases |  | € 223,300 | $ 235.8 |  |  |  |  |  |  |  |  |  |  |  | € 0 | 353,377 | 46,231 |  | € 557,200 |  |
Capital increases |  | 202,000 | 212.2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments for share issue costs |  | € 21,300 | $ 23.6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Free Shares (AGA) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of share-based compensation plans issued | plan |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |
Number of instruments issued (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,601,296 | 1,946,125 |  |  | 4,547,421 |  |  |
ADS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase from issuance of ordinary shares (in shares) | shares |  | 18,699,460 | 18,699,460 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares received per ADS (in shares) | shares |  | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issue of equity, offering price per share (in dollar/euro per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 11.60
Ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase from issuance of ordinary shares (in shares) | shares |  | 1,626,040 | 1,626,040 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issue of equity, offering price per share (in dollar/euro per share) | € / shares |  | € 10.9864 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Kreos 1, convertible bond loans, tranche A |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of other share warrants repurchased (in shares) | shares |  |  |  |  |  |  |  | 43,070 |  |  |  |  |  |  |  |  |  |  |  |  |
Exercises of share warrants (in shares) | shares |  |  |  |  |  |  |  | 67,887 |  |  |  |  |  |  |  |  |  |  |  |  |
Kreos 1, convertible bond loans, tranche B |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of other share warrants repurchased (in shares) | shares |  |  |  |  |  |  |  | 43,070 |  |  |  |  |  |  |  |  |  |  |  |  |
Exercises of share warrants (in shares) | shares |  |  |  |  |  |  |  | 31,696 |  |  |  |  |  |  |  |  |  |  |  |  |
Repayments of convertible loan notes |  |  |  | 8,000 |  | € 7,661 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Kreos & Claret financing |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Borrowings, maximum borrowing capacity |  |  |  |  |  |  | € 75,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate exercise price |  |  |  | 4,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Kreos & Claret financing | Kreos C BSA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of other share warrants | € 4,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Kreos & Claret financing | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate exercise price |  |  |  |  |  |  | € 8,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Heights convertible notes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity issuance, subscripion price per share (in euro per share) | € / shares |  |  |  |  |  |  | € 14.4303 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Borrowings, maximum borrowing capacity |  |  |  |  |  |  | € 75,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from borrowings |  |  |  | 35,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Heights convertible notes | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity issuance, subscripion price per share (in euro per share) | € / shares |  |  |  |  |  |  | € 14.4303 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Kreos / Claret convertible notes (OCABSA) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from borrowings |  |  |  |  | € 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Oceane |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase from issuance of ordinary shares (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  | 1,964,031 |  |  |  |  |  |  |  |  |
Equity issuance, subscripion price per share (in euro per share) | € / shares |  |  |  |  |  |  |  |  |  |  |  | € 30.55 |  |  |  |  |  |  |  |  |
Repayments of convertible loan notes |  |  |  | 25,102 |  |  |  |  |  |  |  |  |  |  |  | 25,000 |  |  |  |  |
Capital increases |  |  |  |  |  |  |  |  |  |  |  | € 60,000 |  |  |  |  |  |  |  |  |
Kreos & Claret financing and Heights convertible notes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from borrowings, net of refinancing of existing indebteness |  |  |  | € 27,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share premium |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase from issuance of ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 352,974 | € 46,176 |  |  |  |
€130.0 million cross-over financing, february 2023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial agreement, amount |  |  |  |  |  |  |  |  | € 130,000 |  |  |  |  |  |  |  |  |  |  |  |
Capital increase from issuance of ordinary shares |  |  |  |  |  |  |  |  | € 130,000 |  |  |  |  |  |  |  |  |  |  |  |
Capital increase from issuance of ordinary shares (in shares) | shares |  |  |  |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Par value per share (in euro per share) | € / shares |  |  |  |  |  |  |  |  | € 0.01 |  |  |  |  |  |  |  |  |  |  |  |
Equity issuance, subscripion price per share (in euro per share) | € / shares |  |  |  |  |  |  |  |  | € 6.50 |  |  |  |  |  |  |  |  |  |  |  |
€130.0 million cross-over financing, february 2023 | Share premium |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issue related cost |  |  |  |  |  |  |  |  | € 6,700 |  |  |  |  |  |  |  |  |  |  |  |
€49.2 million cross-over financing, september 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial agreement, amount |  |  |  |  |  |  |  |  |  |  | € 49,200 |  |  |  |  |  |  |  |  |  |
Capital increase from issuance of ordinary shares (in shares) | shares |  |  |  |  |  |  |  |  |  |  | 5,530,000 |  |  |  |  |  |  |  |  |  |
Par value per share (in euro per share) | € / shares |  |  |  |  |  |  |  |  |  |  | € 0.01 |  |  |  |  |  |  |  |  |  |
Equity issuance, percentage of current share capital |  |  |  |  |  |  |  |  | 89.60% |  | 33.00% |  |  |  |  |  |  |  |  |  |
Equity issuance, subscripion price per share (in euro per share) | € / shares |  |  |  |  |  |  |  |  |  |  | € 8.36 |  |  |  |  |  |  |  |  |  |
Financial agreement, number of transactions | transaction |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |
Capital increases |  |  |  |  |  |  |  |  |  |  | € 46,200 |  |  |  |  |  |  |  |  |  |
€49.2 million cross-over financing, september 2022 | Share premium |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issue related cost |  |  |  |  |  |  |  |  |  |  | € 3,300 |  |  |  |  |  |  |  |  |  |
€150.0 million financing, august 2023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial agreement, amount |  |  |  |  |  |  | € 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial agreement, number of transactions | transaction |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Aggregate Exercise Price, Other Equity Instruments Granted + References No definition available. + Details
Name: | abvx_AggregateExercisePriceOtherEquityInstrumentsGranted
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Borrowings, Maximum Borrowing Capacity + References No definition available. + Details
Name: | abvx_BorrowingsMaximumBorrowingCapacity
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Issuance, Percentage Of Current Share Capital + References No definition available. + Details
Name: | abvx_EquityIssuancePercentageOfCurrentShareCapital
Namespace Prefix: | abvx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Equity Issuance, Subscription Price Per Share + References No definition available. + Details
Name: | abvx_EquityIssuanceSubscriptionPricePerShare
Namespace Prefix: | abvx_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Financial Agreement, Amount + References No definition available. + Details
Name: | abvx_FinancialAgreementAmount
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Financial Agreement, Number Of Transactions + References No definition available. + Details
Name: | abvx_FinancialAgreementNumberOfTransactions
Namespace Prefix: | abvx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase + References No definition available. + Details
Name: | abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease
Namespace Prefix: | abvx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants + References No definition available. + Details
Name: | abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants
Namespace Prefix: | abvx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Issuance Of Other Share Warrants + References No definition available. + Details
Name: | abvx_IssuanceOfOtherShareWarrants
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Issue Of Equity, Offering Price Per Share + References No definition available. + Details
Name: | abvx_IssueOfEquityOfferingPricePerShare
Namespace Prefix: | abvx_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Other Share Warrants Repurchased + References No definition available. + Details
Name: | abvx_NumberOfOtherShareWarrantsRepurchased
Namespace Prefix: | abvx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Share-Based Compensation Plans Issued + References No definition available. + Details
Name: | abvx_NumberOfShareBasedCompensationPlansIssued
Namespace Prefix: | abvx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Shares Received Per ADS + References No definition available. + Details
Name: | abvx_NumberOfSharesReceivedPerADS
Namespace Prefix: | abvx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds From Borrowings, Net Of Refinancing Of Existing Indebteness + References No definition available. + Details
Name: | abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Proceeds From Issuing Shares Other Than Through Exercise Of Warrants + References No definition available. + Details
Name: | abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Repayments Of Convertible Loans Notes + References No definition available. + Details
Name: | abvx_RepaymentsOfConvertibleLoansNotes
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase in equity through the issue of equity instruments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 106 -Subparagraph d -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_IssueOfEquity
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 45 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 47 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The nominal value per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 79 -Subparagraph a -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ParValuePerShare
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow for share issue costs. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 17 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_PaymentsForShareIssueCosts
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from borrowings obtained. [Refer: Borrowings] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from issuing shares. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProceedsFromIssuingShares
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of cost related to the issuance of shares. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 106 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ShareIssueRelatedCost
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_FreeSharesAGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=abvx_AmericanDepositorySharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=abvx_Kreos1ConvertibleBondLoansTrancheBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abvx_WarrantsAxis=abvx_KreosCBSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=abvx_HeightsConvertibleNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingTrancheAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=abvx_OCEANEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abvx_FinancialAgreementAxis=abvx_A130.0MillionCrossOverFinancingFebruary2023Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abvx_FinancialAgreementAxis=abvx_A49.2MillionCrossOverFinancingSeptember2022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abvx_FinancialAgreementAxis=abvx_A150.0MillionFinancingAugust2023Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |